| 4.62 -0.02 (-0.43%) | 01-14 09:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.75 | 1-year : | 7.88 |
| Resists | First : | 5.77 | Second : | 6.75 |
| Pivot price | 3.81 |
|||
| Supports | First : | 4.11 | Second : | 3.07 |
| MAs | MA(5) : | 4.24 |
MA(20) : | 3.7 |
| MA(100) : | 2.36 |
MA(250) : | 1.69 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 48.5 |
D(3) : | 41.4 |
| RSI | RSI(14): 69.5 |
|||
| 52-week | High : | 5.77 | Low : | 0.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IRWD ] has closed below upper band by 12.3%. Bollinger Bands are 155.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.72 - 4.74 | 4.74 - 4.76 |
| Low: | 4.32 - 4.34 | 4.34 - 4.36 |
| Close: | 4.61 - 4.64 | 4.64 - 4.68 |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Wed, 07 Jan 2026
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating - MarketBeat
Tue, 06 Jan 2026
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry - simplywall.st
Mon, 05 Jan 2026
Citizens Upgrades Ironwood Pharmaceuticals (IRWD) - Nasdaq
Mon, 05 Jan 2026
Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 - Finviz
Mon, 05 Jan 2026
Ironwood Pharmaceuticals (IRWD) Upgraded to Market Outperform by Citizens | IRWD Stock News - GuruFocus
Fri, 02 Jan 2026
Ironwood Pharmaceuticals: Market Response to Legal Settlement - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 163 (M) |
| Held by Insiders | 1.1838e+008 (%) |
| Held by Institutions | 2.6 (%) |
| Shares Short | 7,150 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 46.79 |
| Profit Margin | 8.4 % |
| Operating Margin | 63.6 % |
| Return on Assets (ttm) | 22.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 33.2 % |
| Gross Profit (p.s.) | 1.91217e+009 |
| Sales Per Share | 1.88328e+009 |
| EBITDA (p.s.) | 8.09333e+008 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 68 (M) |
| PE Ratio | 25.77 |
| PEG Ratio | 0 |
| Price to Book value | 0.09 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.52 |
| Dividend | 0 |
| Forward Dividend | 7.33e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|